Kornimate/medical-research-clean huggingface dataset:
perioperative music therapy plus oxycodone in perioperative management of lung surgery

Conditions: Analgesia; Lung Cancer

Summary: to explore the feasibility and effectiveness of perioperative music therapy plus oxycodone in pain management after thoracic surgery, patients will be randomly assigned into two groups. the experimental group will receive perioperative music therapy and the control group will not. we will record and contrast the postoperative oxycodone usage to evaluate the effect of music therapy in relieving the pain. we will also use visual analogue scale, questionnaire and eeg to evaluate patients' anxiety and depression.


Eligibility criteria:
inclusion criteria: * enhanced ct or pet/ct indicate primary malignant pulmonary nodule; * the clinical stage belongs to ct1-4n0-2m0 before treatment or yct1-4n0-2m0 after neoadjuvant treatment (ajcc/tnm 8th edition); * suitable for video-assisted thoracoscopic surgery after evaluated by thoracic surgeon; * fev1 \> 1.5l and dlco \> 60% pred; * hearing loss lesser than 35 decibels (db) in the better hearing ear; * eastern cooperative oncology group (ecog) performance status of 0 to 2; * american society of anesthesiologists score of 1 or 2; * confirmed eligibility for r0 resection for curative intent by thoracic surgeon assessment; * adequate cardiopulmonary function, confirmed to meet the requirement for surgical resection for curative intent; * able to provide written informed consent and able to understand and agree to comply with study requirements and evaluation forms; * life expectancy greater than 12 months exclusion criteria: * enhanced ct or pet/ct indicate metastatic malignant pulmonary nodule; * hearing loss greater than 35 decibels (db) in the better hearing ear; * active autoimmune disease or history of autoimmune disease that may recur; note: well-controlled type 1 diabetes is allowed; hypothyroidism (controlled with thyroid hormone replacement only); well-controlled celiac disease; skin disease not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia); any other condition that is not expected to recur in the absence of an external trigger. * history of interstitial lung disease, pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease; * serious infection occurred before grouping, including but not limited to hospitalization due to infectious complications, bacteremia or severe pneumonia; severe chronic or active infection (including pulmonary tuberculosis infection, etc.) requiring systemic (oral or intravenous) antibiotics within 14 days before grouping; * simultaneous participation in another therapeutic clinical study; * pregnant or lactating women, or male and female patients planning to have children during the study; * other conditions that the investigators consider inappropriate for participation in this trial, such as poor compliance.

Keywords: music therapy anxiety quality of life
exercise and tumor blood flow

Conditions: Tumor Blood Flow at Rest and During Exercise

Summary: this research aims at investigating tumor blood flow response to acute exercise in human cancer patients. it is hypothesized and expected that acute exercise increases tumor blood flow, which could plausibly increase the efficacy of cancer treatment.

physical activity has been applied as an adjunctive therapy in the secondary prevention of many cancers, but very little is currently known clinically and mechanistically about the effects of physical activity and exercise on tumor itself. based on recent evidence from pre-clinical studies, it is plausible to expect that changes in tumor blood flow and its heterogeneity, oxygenation, and metabolism due to exercise would increase the delivery of chemotherapy and other cancer drugs into the tumor increasing the efficacy of cancer treatment. eight (8) newly diagnosed hodgkin lymphoma cancer patients will be recruited to investigate whether these pre-clinical findings can be extended to humans to serve as an evidence-based proof-of-concept for the possible inclusion of exercise in the treatment of cancer during chemotherapy. to study the effect of acute physical exercise on tumor blood flow and its heterogeneity, supine bicycle exercise in a positron emission tomography (pet) scanner will be used to exercise hodgkin lymphoma cancer patients. these experiments are additional measurements to their normal treatments, and no new interventional approaches will be conducted in this study. the study consists of one fitness test assessment, and tumor blood flow measurements with pet at rest and during supine cycling exercise.

Eligibility criteria:
inclusion criteria: * newly diagnosed hodgkin lymphoma exclusion criteria: * abnormal fatigue, anemia, or physical dysfunction due to the disease

Keywords: clinical trial positron emission tomography exercise
elucidating the temporality of structural and functional connectivity changes in essential tremor after successful deep brain stimulation to the dentato-rubro-thalamic tract

Conditions: Essential Tremor

Summary: the purpose of this study is to elucidate the structural connectivity of the dentato-rubro-thalamic tract (drtt) and to detect functional network changes due to drtt stimulation


Eligibility criteria:
inclusion criteria: * the diagnosis of essential tremor, made by a movement disorder neurologist, where tremor is not secondary to any disease process or traumatic insult * distal appendicular tremor, with minimal proximal component * tremor refractory to multiple medication regimens and/or where the medications cause intolerable side effects * tremor judged to be severely impacting their quality of life. exclusion criteria: * significant neurological disorder * significant dementia or neurocognitive limitations as assessed by neuropsychiatry (when necessary) * severe psychiatric illness with suicidal ideations * previous surgery to destroy the target region of the brain * surgical contraindications to dbs * current major medical problems that affect brain anatomy,neurochemistry, or function, e.g., liver insufficiency, kidney insufficiency, cardiovascular problems, systemic infections, cancer, hypothyroidism, auto-immune diseases, and any current of history of brain disorder (seizure disorder, stroke, dementia, meningitis, encephalitis, degenerative neurologic diseases and head injury with loss of consciousness for any period of time) * family history of hereditary neurologic disorder, besides essential tremors et * floating metallic objects in the body * pregnancy * alcohol or substance abuse/dependence in the past 6 months.

Keywords: deep brain stimulation
the effect of vitamin c and e therapy on restless leg syndrome in patients with end stage renal disease on haemodialysis

Conditions: Restless Legs Syndrome; End Stage Renal Disease

Summary: this study aims to measure the effectiveness of vitamins c and e on relieving rls symptoms in end stage renal disease patients on hd

double-blind placebo-controlled trial of 12 weeks duration on end stage renal disease (esrd) patients on hd with rls. all esrd patients on hd will be screened clinically for rls using the five diagnostic criteria of irlssg by trained physicians. then the quastioniare will be filled and inclusion and exclusion criteria be checked sleep study must be done. each patient will then undergo a full sleep study using level 2 polysomnography at home. periodic leg movements with sleep (plms) index and leg movements index (lm) before sleep onset will be recorded as well as other variables then subjects will then be randomly assigned by blocked randomization into four groups, each group will include 40 patients. a. group 1: will receive vitamin c (200 mg) tablet and vitamin e (a-tocopherol) (400 mg) capsule every day for 12 weeks. b. group 2: will receive vitamin e (400 mg) capsule and placebo every day for 12 weeks. c. group 3: will receive vitamin c (200 mg) tablet and placebo every day for 12 weeks. d. group 4: will receive two placebo every day for 12 weeks. of note, the personal responsible for randomization will not be involved in the trial.

Eligibility criteria:
inclusion criteria: * end stage renal disease patients on hemodialysis who met the five diagnostic criteria of rls. exclusion criteria: * secondary causes of rls medications (list included in section c below) iron deficiency or peripheral neuropathy presence of rls-mimicking disorders: 1. arthritis 2. deep venous thrombosis 3. varicose veins or venous insufficiency 4. habitual foot tapping patients receiving medications that could trigger rls: 1. anticonvulsants, e.g., new use of anticonvulsant drugs within6 months of screening. a stable regimen of anticonvulsants was allowed. 2. antipsychotics (haloperidol or phenothiazine derivatives) 3. antidepressants (selective serotonin reuptake inhibitors or tricyclic antidepressants) 4. antimanic (lithium) patients on medications or with conditions that may interfere with vitamin c \& e absorption: 1. celiac disease 2. crohn's disease 3. chronic pancreatitis 4. cystic fibrosis 5. weight-reduction drugs 6. chemotherapy and radiotherapy patients with contraindications for vitamin c \& e supplements: 1. blood disorders, e.g., thalassemia, g6pd, sickle cell disease and hemochromatosis 2. other conditions like diabetic patients, oxalate nephropathy, nephrolithiasis and vitamin e or c allergy 3. unstable vital signs 4. retinal eye disease 5. cancers 6. liver disease 7. vitamin k deficiency for women only: 1. pregnancy (positive pregnancy test at screening) 2. currently breastfeeding 3. use of oral contraceptives or start of menopausal hormone therapy within 3 months of baseline history of vitamin e or c intolerance
oxidative stress in robot-assisted laparoscopic radical prostatectomy

Conditions: Oxidative Stress

Summary: gut hypoperfusion - reperfusion injury is an unavoidable event at the end of laparoscopic surgery. it produces oxidative stress (reactive oxygen species). malondialdehyde have been demonstrated to be a reliable biomarker for the evaluation of oxidative stress in vivo. propofol (2, 6 - diisopropylphenol), a highly liposoluble anaesthetic, has a potent antioxidant activity against lipid peroxidation in both in vitron and in vivo studies. on the basis of this knowledge, the investigators hypothesized that propofol has preventive effect for gut hypoperfusion - reperfusion induced injury in robot-assisted laparoscopic radical prostatectomy.

increased intrabdominal pressure is associated with pneumoperitoneum for laparoscopic procedures and is one of the main factors in impairment of splanchnic perfusion by compressing vessels. an hypoperfusion - reperfusion human model is observed during and soon after laparoscopic surgery. after deflation of the abdomen, intrabdominal pressure and splanchnic blood flow normalize, representing reperfusion. reactive oxygen species is produced in metabolic and physiologic processes, and harmful oxidative reactions may occur in organisms that remove them via enzymatic and nonenzymatic antioxidative mechanisms. propofol (2, 6 - diisopropylphenol), a highly liposoluble anaesthetic, has a potent antioxidant activity against lipid peroxidation in both in vitron and in vivo studies. propofol also attenuates ischemia - reperfusion induced lipid peroxidation in humans. on the basis of this knowledge, we hypothesized that propofol has preventive effect for gut hypoperfusion - reperfusion induced injury in robot-assisted laparoscopic radical prostatectomy.

Eligibility criteria:
inclusion criteria: * patients receiving robot-assisted laparoscopic radical prostatectomy in asa ii-iii physical status exclusion criteria: * history of sepsis or shock, clinically relevant cardiopulmonary disease, persistent tobacco abuse, recent antioxidant or vasoconstrictor use

Keywords: robot assisted laparoscopic radical prostatectomy hypoperfusion reperfusion injury, propofol oxidative stress
non randomized comparative study with control

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation

Summary: nk cells are lymphocytes who play a role in the control of viral infections , tumor and fœtal tolerance. they belong to innate immune cells but they have a link with adaptative immunity. indeed, after some viral infections such as cmv, chikungunya, b hepatitis etc, a subset of nkg2c+ nk cells expands and can transfer, in murine models, a " memory " that can better control cmv infections. cmv reactivation is a major cause of morbidity and mortality after allogeneic hematopoietic ste cell transplantation in humans. the aim of this prospective study is to evaluate the role of nk cells, in particular nkg2c+ nk cells in the control of cmv but also adenovirus after allo hsct. peripheral nk cells from 30 and 10 patients who reactivated respectively cmv and adv are prospectively studied (extensive phenotyping and functional studies before and after administration of anti viral drugs) and compared with 30 allotransplanted patients who didn't reactivate cmv in a pair analysis, and 30 healthy donors serologically + for cmv.

for both groups: 28ml of peripheral blood samples are collected at different points. group 1 : before and after anti viral treatment . control group 2: one point after allo-hsct; control group 3: 1 point before transplant. phenotypical study of nk cells: activating and inhibitory receptors, activation and differentiation's markers. phenotypical studies of the ligands on infected cells. genotypic study of kir receptors (kirotype); functional studies: polyfunctionality essay (flow cytometry): degranulation cd107a, ifng, tnfa production).

Eligibility criteria:
inclusion criteria: 1. patients who reactivate cmv or adv after allogeneic hsct ; * age\>18 years; indication for a antiviral treatment: * at least 1 pcr cmv\>1000 copies/ml or 1 pcr adv\>1000 copies/ml or at least 2 adv pcr positive - sites (stools, throat, urines); * signed informed consent; 2. control group: allogeneic hsc transplanted patients; * age\>18 years; no cmv or adv reactivation ; * signed informed consent; 3. healthy donors group: hsc donor; * age\>18 years; * signed informed consent exclusion criteria: none

Keywords: nk cells cytomegalovirus adenovirus allogeneic transplantation
trial of the ovicidal activity of three head lice products (neutralice lotion®, neutralice advance® and moov head lice solution®) after a single application

Conditions: Head Lice

Summary: the purpose of this study is to compare the ovicidal activity of three head lice treatment products. the study population will consist of queensland primary school-aged children (grades 1 - 7) who have at least 20 live eggs on the hair and who have not used any head lice product in the four weeks prior to the study. enrollment will continue to achieve 30 subjects in each treatment group (total of 90 subjects).

subjects will be examined for the presence of head louse eggs. those subjects who have at least 20 live eggs will be randomised into one of 3 treatment groups: neutralice lotion, neutralice advance or moov head lice solution treatment groups. pre-treatment: 10 eggs will be removed from the head by cutting the single hair with the live egg attached, before the treatment. treatment: the subject will then receive a single treatment application according to manufacturers instructions. then the treatment will be washed from the hair as per the manufacturer's instructions. post-treatment: at least 10 treated (live) eggs will be removed from the head by cutting the single hair with the egg attached, after the treatment. all of the eggs will be held in an incubator for 14 days. the proportion of eggs which hatch after 14 days will be compared for the pre-treatment and post-treatment eggs. demographic data will be collected for each subject (hair type, hair colour, hair length, subject age, subject sex) to investigate the affect of hair type on ovicidal efficacy.

Eligibility criteria:
inclusion criteria: * male or female primary school-aged children. * presence of at least 20 live head lice eggs on the hair. the presence of live head lice eggs will be determined from a visual inspection of the hair. * parent / guardian have given written informed consent to their child's participation in the trial. exclusion criteria: * history of allergies or adverse reactions to head lice products or the components of the specific products being tested. * treatment with any head lice product in the 4 weeks prior to participation in this trial. * treatment with hair dyes and bleaches within 4 weeks prior to participation in this trial. * presence of scalp disease(s).

Keywords: ovicide head lice infestation
use of a ureteral access sheath during ureteroscopy and its effect on stone free rate

Conditions: Urinary Calculi

Summary: patients with upper ureteral or renal stones will be randomized to undergoing ureteroscopy with or without a ureteral access sheath. the sheath is designed to facilitate ureteroscope insertion and re-insertion, thus allowing fragments to be basketed out. stone free rates at 3 months will be determined between the two groups. the investigators hypothesize that the use of the ureteral access sheath with ureteroscopy will result in improved stone free rates at 3 months compared to ureteroscopy without use of a sheath.


Eligibility criteria:
inclusion criteria: * upper ureteral (proximal to iliac vessels/iliac crest) calculi; * renal calculi; * normal renal function; * any stone composition; * single or multiple stones(planned treatment of all stones at this surgery); * age \> 18 years; * able and willing to return treatment centre for follow-up visits; and * signed study consent exclusion criteria: * ureteric calculi distal to the level of the iliac vessels/iliac crest; * failed ureteroscopy for same stone (i.e. has to be the first ureteroscopic procedure for this stone, however a prior failed extracorporeal shockwave lithotripsy (swl) is acceptable); * bilateral ureteroscopy; * if an adjunctive procedure is planned post ureteroscopy (e.g. percutaneous nephrolithotomy, swl) (i.e. it is known preoperatively that a ureteroscopic procedure will not render the patient stone free and that ancillary procedures will be necessary); * if in the investigators opinion, enrollment would be not be appropriate; or * pregnancy

Keywords: ureteroscopy stone free
applying speed of processing training to individuals with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this pilot study will document the efficacy of a behavioral intervention for processing speed (ps) in multiple sclerosis (ms), speed of processing training (spt), which has been successful used in the aging population in several studies. this study will (1) apply a treatment protocol for ps impairments, well-validated in aging, to persons with ms with impaired ps, and document its efficacy on standard neuropsychological (np) tests (2) assess the effectiveness of the intervention utilizing global measures of daily life, including an objective measure (tiadl) (3) examine the long term impact of spt. this study is unique in that it will be the first to evaluate the efficacy of a highly-manualized structured behavioral treatment for processing speed deficits in persons with ms utilizing the optimal methodology for carrying out such studies, a randomized clinical trial. given the prevalence of ps deficits in the ms population and the significant impact such deficits have on everyday functioning, public safety, and overall quality of life, the identification of an effective intervention for ps deficits in ms could have a profound impact on the population and society as a whole.


Eligibility criteria:
inclusions: * diagnosis of multiple sclerosis * fluent in english * processing speed impairment (based on evaluation). exclusions: * currently taking steroids and /or benzodiazepines * prior stroke or neurological disease * history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of major depressive disorder, schizophrenia, bipolar disorder i or ii * significant alcohol or drug abuse history

Keywords: processing speed intervention multiple sclerosis cognition
mce for gastric examination in obese people

Conditions: Obesity

Summary: this retrospective study aimed to evaluate the feasibility and safety of mce for the detection of gastric disease in obese people.

in this study, we evaluated the feasibility and safety of mce for the detection of gastric disease in obese people by comparing the results of mce between healthy weight people (18.5≤bmi\<25) and obese people (bmi≥30). the observation index included mucosal visualization, gastric transit time, cleanliness of the stomach, detection of lesions and safety evaluation.

Eligibility criteria:
inclusion criteria: * 18.5≤bmi\<25 or bmi≥30 * underwent gastric examination; * at least 18 years old； * be able to provide informed consent. exclusion criteria: * with swallowing obstruction or disorders; * with known or suspected gastrointestinal obstruction, stenosis and fistula; * have no conditions for surgery or refuse to undergo any abdominal surgery; * be allergic to or have other known contraindication or intolerance to the drug used in the study; * with pacemakers or other electronic devices such as electronic cochlear implants, implanted magnetic metal drug infusion pumps, neurostimulators, and magnetic metal foreign bodies; * women during pregnancy; * currently enrolled in another clinical trial of a drug or device; * other conditions determined by the investigator to be inappropriate for enrollment.
reduction or extension of conduction time with ventricular electromechanical remodeling (recover)

Conditions: Heart Failure

Summary: this prospective multicenter registry study aims to detect the serial changes in ventriculo-ventricular conduction times according to cardiac-resynchronization therapy response.


Eligibility criteria:
inclusion criteria: * meeting the current esc or accf/aha/hrs class i or class iia indications for cardiac-resynchronization (crt) implant exclusion criteria: * myocardial infarction, unstable angina within 40 days prior the enrollment * recent cardiac revascularization in the 4 weeks prior to the enrollment or planned for the 3 months following * cerebrovascular accident (cva) or transient ischemic attack (tia) in the 3 months prior to the enrollment * primary valvular disease requiring surgical correction * pregnant or are planning during the duration of the investigation * status 1 candidate for cardiac transplantation or consideration for transplantation over the next 12 months * post-cardiac transplantation * life expectancy \< 12 months * currently participating in any other clinical investigation except for observational registry
effect of magnesium supplementation for children with drug resistant idiopathic epilepsy

Conditions: Drug Resistant Epilepsy

Summary: effect of oral magnesium sulfate (mg) supplementation will be studied. children with drug resistant idiopathic epilepsy following up in pediatric neurology clinic, ain shams university, will be randomized to either mg add-on treatment group or anti-epileptic drugs aeds alone. serum magnesium, seizure control and intelligent quotation (iq) will be done at base line and after 6 months of treatment.

the aim of this work was to study the effect of magnesium as add on therapy on clinical seizure control in drug resistant idiopathic epilepsy and iq.

Eligibility criteria:
inclusion criteria: * children with drug resistant idiopathic epilepsy exclusion criteria: * structural, metabolic, infectious and unknown etiology epilepsy * any neurological disease other than epilepsy * any nutritional disorder * any other systemic diseases (including renal disease, cardiac arrhythmia) * drug intake other than antiepileptic drugs (aed)

Keywords: children iq idiopathic epilepsy magnesium supplementation seizure control chalfont score